Immune Responce in Mice Immunized with Live Cold-Adapted Influenza Vaccine in Combination with Chitosan-Based Adjuvants

An influence of intranasal combined injection of live cold-adapted influenza vaccine with chitosan derivatives as adjuvants on the subpopulation structure of mononuclear leukocytes of mouse spleen which reflects the orientation of the immune response was studied. It is found that the inclusion of chitosan preparations promotes activation of cellular-level of immune response.

Authors:

• Nelly К. Akhmatova
• Оlga V. Lebedinskaya
• Ancha V. Baranova
• Еlena А. Lebedinskaya
• Ekaterina V. Sorokina
• Elvin А. Akhmatov
• Аnatoliy P. Godovalov
• Stanislav G. Markushin

Keywords:

• Immunophenotype
• chitosan
• cold-adapted vaccine
• intranasal injection.

References:

[1] N.K. Akhmatova, N.B. Egorova, E.A. Kurbatova, I.B. Semenova, O.M.
Kuz'menko, R.V. Shcherbakov, S.G. Markushin, Iu.Z. Gendon,
"Influence of chitosan on immunophenotype and functional activity of
murine mononuclear leukocytes after immunization with inactivated
influenza vaccine", Zh. Mikrobiol. Epidemiol. Immunobiol. Nov-
Dec;(6), 2008, pp. 31-35.
[2] S.G. Markushin, Iu.Z. Gendon, G.G. Krivtsov, I.I. Akopova, A.S.
Sukhno, A.D. Pereverzev, "Increase of immunogenicity of cold-adapted
influenza vaccine by using adjuvant", Zh. Mikrobiol. Epidemiol.
Immunobiol. Sep-Oct ;(5), 2010, pp. 29-34.
[3] A. Bacon, J. Makin, P.J. Sizer, I. Jabbal-Gill, M. Hinchcliffe, L. Illum, S.
Chatfield, M. Roberts, "Carbohydrate biopolymers enhance antibody
responses to mucosally delivered vaccine antigens", Infect. Immun., vol.
68, 2000, pp. 5764-5770.
[4] Y. Ghendon, S. Markushin, G. Krivtsov, I. Akopova, "Chitosan as an
adjuvant for parenterally administered inactivated influenza vaccines",
Arch. Virol., vol. 153, 2008, pp. 831-837.
[5] Y. Ghendon, S. Markushin, Y. Vasiliev, I. Akopova, I. Koptiaeva, G.
Krivtsov, O. Borisova, N. Ahmatova, E. Kurbatova, S. Mazurina, V.
Gervazieva, "Evaluation of properties of chitosan as an adjuvant for
inactivated influenza vaccines administered parenterally", Journal of
Medical Virology, vol. 81, 2009, pp. 494-506.
[6] R. Gupta, G. Siber, "Adjuvant for human vaccines -current status,
problems and future prospects", Vaccine, vol. 13, 1995, pp. 1263-1276.
[7] L. Illum, "Nasal drug delivery - possibilities, problems and solutions", J.
Control. Release, vol. 87, 2003, pp. 187-198.
[8] L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A.N. Fisher, S.S. Davis,
"Chitosan as a novel nasal delivery system for vaccines", Adv. Drug.
Deliv. Rev., vol. 51, 2001, pp. 81-96.
[9] I.M. van der Lubben, J.C. Verhoef, G. Borchard, H.E. Junginger,
"Chitosan and its derivatives in mucosal drug and vaccine delivery",
Europ. J. Pharm. Sci., vol. 14, 2001, pp. 201-207.
[10] I.M. van der Lubben, G. Kersten, M.M. Fretz, C. Beuvery, J. Coos
Verhoef, H.E. Junginger, "Chitosan microparticles for mucosal
vaccination against diphtheria: oral and nasal efficacy studies in mice",
Vaccine, vol. 21, 2003, pp. 1400-1408.
[11] S.A. Kopecky-Bromberg, K.A. Fraser, N. Pica, E. Carnero, T.M. Moran,
R.W. Franck, M. Tsuji, P. Palese, "Alpha-C-galactosylceramide as an
adjuvant for a live attenuated influenza virus vaccine", Vaccine, vol.
8;27(28), pp. 3766-3774.
[12] A.R. Rekstin, K. Lu, D. Kats, L.G..Rudenko "Production of early
cytokines after infection with A/Leningrad/134/57 (H2N2) wide-type
virus and cold-adapted attenuated vaccine viruses", Vopr. Virusol. Mar-
Apr; 51(2), 2006, pp. 27-30.